Shots:

• The company has completed enrollment in the P-II CATALINA study evaluating the safety and efficacy of NGM621 (IVT injections- q4w/ q8w) vs sham control in 320 patients with geographic atrophy secondary to AMD. The results are expected in H2’22
• The 1EPs of the P-II CATALINA study is the rate of change in geographic atrophy lesion area as measured by FAF imaging @52 wks. of treatment & will evaluate the incidence and severity of ocular and systemic AEs
• Additionally- the P-I results demonstrate that the therapy was well-tolerated and had an acceptable safety profile. NGM621 is a mAb engineered to inhibit complement C3

  | Ref: Globe Newswire | Image: NGM Biopharmaceuticals